Serum and Urine Levels of Vascular Endothelial Growth Factor as Prognostic Markers in Patients with Bladder Cancer
| Autor: | Mohsen Ayati, Hossein Ghorani, Erfan Amini, Mohammad Reza Nowroozi, Hassan Jamshidian, Solmaz Ohadian Moghadam |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Middle East Journal of Cancer, Vol 11, Iss 2, Pp 198-202 (2020) |
| Druh dokumentu: | article |
| ISSN: | 2008-6709 2008-6687 |
| DOI: | 10.30476/mejc.2019.81265.0 |
| Popis: | Background: Bladder cancer is the second most common urinary cancer after prostate cancer. Recent studies have shown higher serum and urinary vascular endothelial growth factor (VEGF) in increased angiogenesis. In this study, the mean serum and urine level of VEGF was assessed in patients with bladder cancer. Methods: In this case-control study, 46 patients with bladder cancer referred to Imam-Khomeini Hospital in Tehran, Iran and 38 subjects as control, were enrolled and the mean serum and urine level of VEGF was assessed and compared between the groups. Results: The mean serum level of VEGF was 478.7, 518.4, and 648.1 in control, low-grade, and high-grade groups, respectively, with no significant difference (P=0.175). The mean urine level of VEGF was 414.2, 968.3, and 848.4 in control, low-grade, and high-grade groups, respectively, with significant difference (P=0.010). Conclusion: The mean urine level of VEGF in patients with bladder cancer is higher than healthy subjects. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|